IDH3A and acute myeloid leukemia: This approach has had remarkable success with the clinical approval of the drug Idhifa (Enasidenib, Agios Pharmaceuticals/Celgene) in 2017, which targets a mutated form of isocitrate dehydrogenase (IDH) 2 for the treatment of relapsed/refractory acute myeloid leukemia (AML).4